Top Stories
VDPHL01, an extended-release oral formulation of minoxidil, the same active ingredient in Rogaine, met all its primary and secondary endpoints in a Phase III trial.
The company said the APOLLO results address concerns that had derailed the drug's accelerated-approval bid for patients with a rare photosensitivity disorder.
ABBV-466, which combines IL-23 inhibitor Skyrizi with α4β7 inhibitor trosunilimab, delivered higher endoscopic remission rates than either component alone after 12 weeks.
The collaboration covers two preclinical ADC candidates from Hansoh and multiple additional programmes based on targets proposed by Roche.
The fresh capital will help NOUS-209 move into a registration-enabling study for cancer interception in Lynch syndrome carriers.
Conference News
QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced pr...
– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment –– Real-World Evidence Provides Insight into Early U.S....
Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumorsSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant...
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Data featured as a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear MedicineFirst-in-human imaging performed in 10 patients with non-small cell lung cance...
